Carotid artery atherosclerosis: What is the evidence for drug action?

Current Pharmaceutical Design

Volumn 13, Issue 11, 2007, Pages 1141-1159

  Daskalopoulou, Stella S ^a,b   Daskalopoulos, Marios E ^b   Perrea, Despina ^b   Nicolaides, Andrew N ^c   Liapis, Christos D ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF CYPRUS   (Cyprus)

Author keywords

Antihypertensive drugs; Carotid atherosclerosis; High risk plaque; Imaging; Intima media thickness; Lipid lowering drugs; Stroke

Indexed keywords

ACETAZOLAMIDE; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BEZAFIBRATE; CHLORTALIDONE; ENALAPRIL; FLUINDOSTATIN; FOSINOPRIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISRADIPINE; LACIDIPINE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NIFEDIPINE; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERAPAMIL; XENON;

ANGIOPLASTY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ARTERY FLOW; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIET THERAPY; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE MARKER; DOPPLER ECHOGRAPHY; DRUG DOSE COMPARISON; DRUG MECHANISM; ECHOGRAPHY; ELASTOGRAPHY; HIGH RISK PATIENT; HUMAN; INTIMA; ISCHEMIC HEART DISEASE; MAGNETIC RESONANCE ANGIOGRAPHY; MEDLINE; METABOLIC SYNDROME X; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING CESSATION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STENT; THERMOGRAPHY; THICKNESS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CAROTID ARTERY DISEASES; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 34248384880     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780619019     Document Type: Review

References (202)

1. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, et al. Advisory Board of the 3rd Watching the Risk Symposium 2004, 13th European Stroke Conference. Mannheim intima-media thickness consensus. Cerebrovasc Dis 2004; 18: 346-9.
2. Simon A, Levenson J. May subclinical arterial disease help to better detect and treat high-risk asymptomatic individuals? J Hypertens 2005; 23: 1939-45.
3. Devine PJ, Carlson DW, Taylor AJ. Clinical value of carotid intima-media thickness testing. J Nucl Cardiol 2006; 13: 710-8.
4. Chambless LE, Folsom AR, Davis V, Sharrett R, Heiss G, Sorlie P, et al. Risk factors for progression of common carotid atherosclerosis: The Atherosclerosis Risk in Communities study 1987-1998. Am J Epidemiol 2002; 155: 38-47.
5. Davis M, Atwal AS, Nair DR, Jagroop IA, Seifalian AS, Mikhailidis DP, et al. The effect of short term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: A pilot study. Curr Med Res Opin 2000; 16: 198-204.
6. Youssef F, Seifalian AM, Jagroop IA, Myint F, Baker D, Mikhailidis DP, et al. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 2002; 23: 358-64.
7. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) study 1987-1993. Am J Epidemiol 1997; 146: 483-94.
8. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, et al. Carotid wall thickness is predictive of incident clinical stroke: The Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151: 478-87.
9. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
10. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96: 1432-7.
11. Hollander M, Bots ML, del Sol AI, Koudstaal PJ, Witteman JC, Grobbee DE, et al. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: The Rotterdam Study. Circulation 2002; 105: 2872-7.
12. Golledge J, Greenhalgh RM, Davies AH. The symptomatic carotid plaque. Stroke 2000; 31: 774-81.
13. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
14. Davies JR, Rudd JF, Fryer TD, Weissberg PL. Targeting the vulnerable plaque: The evolving role of nuclear imaging. J Nucl Cardiol 2005; 12: 234-46.
15. Mostafa Mtairag E, Chollet-Martin S, Oudghiri M, Laquay N, Jacob MP, Michel JB, et al. Effects of interleukin-10 on monocyte/ endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc Res 2001; 49: 882-90.
16. Daskalopoulou SS, Daskalopoulos ME, Theocharis S, Kavantzas N, Perrea D, Karandrea D, et al. Metallothionein expression in the high-risk carotid atherosclerotic plaque. Curr Med Res Opin 2007; 23: 659-70.
17. Tegos TJ, Kalodiki E, Daskalopoulou SS, Nicolaides AN. Stroke: epidemiology, clinical picture, and risk factors - Part I of III. Angiology 2000; 51: 793-808.
18. Sacco RL. Newer risk factors for stroke. Neurology 2001; 57(5 Suppl 2): S31-4.
19. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419-24.
20. Paraskevas KI, Daskalopoulou SS, Daskalopoulos ME, Liapis CD. Secondary prevention of ischemic cerebrovascular disease. What is the evidence? Angiology 2005; 56: 539-52.
21. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: A systematic review of tools for clinicians. J Gen Intern Med 2003; 18: 1039-52.
22. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
23. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosElerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-72.
24. Wyman RA, Fraizer MC, Keevil JG, Busse KL, Aeschlimann SE, Korcarz CE, et al. Ultrasound-detected carotid plaque as a screening tool for advanced subclinical atherosclerosis. Am Heart J 2005; 150: 1081-5.
25. Nordestgaard BG, Gronholdt ML, Sillesen H. Echolucent rupture-prone plaques. Curr Opin Lipidol 2003; 14: 505-12.
26. Simon A, Chironi G, Levenson J. Performance of subclinical arterial disease detection as a screening test for coronary heart disease. Hypertension 2006; 48: 392-6.
27. Baldassarre D, Amato M, Pustina L, Castelnuovo S, Sanvito S, Gerosa L, et al. Measurement of carotid artery intima-media thickness in dyslipidemic patients increases the power of traditional risk factors to predict cardiovascular events. Atherosclerosis 2006 May 6; [Epub ahead of print]
28. Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, et al. Prevention ConfIrence V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: Noninvasive tests of atherosclerotic burden: Writing GrouE III. Circulation 2000; 101: e16-22.
29. Geroulakos G, O'Gorman, Kalodiki E, Sheridan DJ, Nicolaides AN. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J 1994; 15: 781-5.
30. Geroulakos G, Ramaswami G, Veller MG, Fisher GM, Renton S, Nicolaides AN, et al. Arterial Wall Changes in Type 2 Diabetic Subjects. Diabetic Med 1994; 11: 692-5.
31. Poli A, Tremoli E, Colombo A, Sirtori M, Pignoli P, Paoletti R. Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patients. A new model for the quantitation and follow-up of preclinical atherosclerosis in living human subjects. Atherosclerosis 1988; 70: 253-61.
32. Poredos P. Intima-media thickness: Indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med 2004; 9: 46-54.
33. Salonen J and Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991; 11: 1245-9.
34. Wittekoek ME, de Groot E, Prins MH, Trip MD, Buller HR, Kastelein JJ. Differences in intima-media thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. Atherosclerosis 1999; 146: 271-9.
35. Kastelein JJP, de Groot E, Sankatsing R. Atherosclerosis measured by B-Mode ultrasonography: Effect of statin therapy on disease progression. Am J Med 2004; 116: 31-6.
36. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 363: 369-70.
37. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Buller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial. JAMA 2004; 292: 331-7.
38. van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, Brooks-Wilson A, et al. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: An observational study. Lancet 2002; 359: 37-42.
39. Hovingh GK, Brownlie A, Bisoendial RJ, Dube MP, Levels JH, Petersen W, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 2004; 44: 1429-35.
40. Ahmad J, Hameed B, Das G, Siddiqui MA, Ahmad I. Postprandial hypertriglyceridemia and carotid intima-media thickness in north Indian type 2 diabetic subjects. Diabetes Res Clin Pract 2005; 69: 142-50.
41. Schillinger M, Exner M, Mlekusch W, Sabeti S, Amighi J, Nikowitsch R, et al. Inflammation and Carotid Artery - Risk for Atherosclerosis Study (ICARAS). Circulation 2005; 111: 2203-9.
42. Kang ES, Kim HJ, Kim YM, Lee S, Cha BS, Lim SK, et al. Serum high sensitivity C-reactive protein is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Res Clin Pract 2004; 66(Suppl 1): S115-20.
43. Konukoglu D, Serin O, Demiriz Kemerli G, Serin E, Hayirhoglu A, Oner B. A study on the carotid artery intima-media thickness and its association with lipid peroxidation. Clin Chim Acta 1998; 277: 91-8.
44. Ohkuma T, Minagawa T, Takada N, Ohno M, Oda H, Ohashi H. C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients. Am J Kidney Dis 2003; 42: 355-61.
45. Steer P, Millgard J, Sarabi DM, Basu S, Vessby B, Kahan T, et al. Cardiac and vascular structure and function are related to lipid peroxidation and metabolism. Lipids 2002; 37: 231-6.
46. Humphries SE, Morgan L. Genetic risk factors stroke and carotid atherosclerosis: Insights into pathophysiology from candidate gene approaches. Lancet Neurol 2004; 3: 227-35.
47. Atger V, Giral P, Simon A, Cambillau M, Levenson J, Gariepy J, et al. High-density lipoprotein subfractions as markers of early atherosclerosis. PCVMETRA Group. Prevention Cardio-Vasculaire en Medecene du Travail. Am J Cardiol 1995; 75: 127-31.
48. Mathiesen EB, Bonaa KH, Joakimsen O. Low levels of high-density lipoprotein cholesterol are associated with echolucent carotid artery plaques: The Tromso study. Stroke 2001; 32: 1960-5.
49. Signorelli SS, Neri S, Di Pino L, Costa MP, Pennisi G, Digrandi D, et al. Oxidative stress and endothelial damage in patients with asymptomatic carotid atherosclerosis. Clin Exp Med 2001; 1: 9-12.
50. Huang ZS, Jeng JS, Wang CH, Yip PK, Wu TH, Lee TK. Correlations between peripheral differential leukocyte counts and carotid atherosclerosis in non-smokers. Atherosclerosis 2001; 158: 431-6.
51. Johnsen SH, Fosse E, Joakimsen O, Mathiesen EB, Stensland-Bugge E, Njolstad I, et al. Monocyte count is a predictor of novel plaque formation: A 7-year follow-up study of 2610 persons without carotid plaque at baseline the Tromso Study. Stroke 2005; 36: 715-9.
52. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck study. Circulation 1999; 100: 1154-60.
53. Yamagami H, Kitagawa K, Nagai Y, Hougaku H, Sakaguchi M, Kuwabara K, et al. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke 2004; 35: 677-81.
54. Gronholdt ML, Sillesen H, Wiebe BM, Laursen H, Nordestgaard BG. Increased acute phase reactants are associated with levels of lipoproteins and increased carotid plaque volume. Eur J Vasc Endovasc Surg 2001; 21: 227-34.
55. With Noto AT, Bogeberg Mathiesen E, Amiral J, Vissac AM, Hansen JB. Endothelial dysfunction and systemic inflammation in persons with echolucent carotid plaques. Thromb Haemost 2006; 96: 53-9.
56. Dosa E. Rugonfalvi-Kiss S, Prohaszka Z, Szabo A, Karadi I, Selmeci L, et al. Marked decrease in the levels of two inflammatory markers, hs-C-reactive protein and fibrinogen in patients with severe carotid atherosclerosis after eversion carotid endarterectomy. Inflamm Res 2004; 53: 631-5.
57. Hashimoto H, Kitagawa K, Kuwabara K, Hougaku H, Ohtsuki T, Matsumoto M, et al. Circulating adhesion molecules are correlated with ultrasonic assessment of carotid plaques. Clin Sci (Lond) 2003; 104: 521-7.
58. DeGraba TJ, Siren AL, Penix L, McCarron RM, Hargraves R, Sood S, et al. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke 1998; 29: 1405-10.
59. Rothwell PM, Gibson R, Warlow CP. Interrelation between plaque surface morphology and degree of stenosis on carotid angiograms and the risk of ischemic stroke in patients with symptomatic carotid stenosis. On behalf of the European Carotid Surgery Trialists' Collaborative Group. Stroke 2000; 31: 615-21.
60. Lovett JK, Gallagher PJ, Hands LJ, Walton J, Rothwell PM. Histological correlates of carotid plaque surface morphology on lumen contrast imaging. Circulation 2004; 110: 2190-7.
61. Waugh JR, Sacharias N. Arteriographic complications in the DSA era. Radiology 1992; 182: 243-6.
62. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke 2005; 36: 2764-72.
63. Yuan C, Mitsumori LM, Beach KW, Maravilla KR. Carotid atherosclerotic plaque: Noninvasive MR characterization and identification of vulnerable lesions. Radiology 2001; 221: 285-99.
64. Trivedi RA, U-King-Im JM, Graves MJ, Horsley J, Goddard M, Kirkpatrick PJ, et al. MRI-derived measurements of fibrous-cap and lipid-core thickness: The potential for identifying vulnerable carotid plaques in vivo. Neuroradiology 2004; 46: 738-43.
65. Cai JM, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 2002; 106: 1368-73.
66. Chu B, Kampschulte A, Ferguson MS, Kerwin WS, Yarnykh VL, O'Brien KD, et al. Hemorrhage in the atherosclerotic carotid plaque: A high-resolution MRI study. Stroke 2004; 35: 1079-84.
67. Fayad ZA, Fuster V. Characterization of atherosclerotic plaques by magnetic resonance imaging. Ann N Y Acad Sci 2000; 902: 173-86.
68. Nederkoorn PJ, van der Graaf Y, Hunink MG. Duplex ultrasound and magnetic resonance angiography compared with digital subtraction angiography in carotid artery stenosis: A systematic review. Stroke 2003; 34: 1324-32.
69. Josephson SA, Bryant SO, Mak HK, Johnston SC, Dillon WP, Smith WS. Evaluation of carotid stenosis using CT angiography in the initial evaluation of stroke and TIA. Neurology 2004; 63: 457-60.
70. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]- fluorodeoxyglucose positron emission tomography. Circulation 2002; 105: 2708-11.
71. Gaitini D, Soudack M. Diagnosing carotid stenosis by Doppler sonography: state of the art. J Ultrasound Med 2005; 24: 1127-36.
72. Sankatsing RR, de Groot E, Jukema JW, de Feyter PJ, Pennell DJ, Schoenhagen P, et al. Surrogate markers for atherosclerotic disease. Curr Opin Lipidol 2005; 16: 434-41.
73. Geroulakos G, Ramaswami G, Nicolaides A, James K, Labropoulos N, Belcaro G, et al. Characterisation of symptomatic and asymptomatic carotid plaques using high-resolution real-time ultrasonography. Br J Surg 1993; 80: 1274-7.
74. Elatrozy T, Nicolaides A, Tegos T, Zarka AZ, Griffin M, Sabetai M. The effect of B-mode ultrasonic image standardisation on the echodensity of symptomatic and asymptomatic carotid bifurcation plaques. Int Angiol 1998; 17: 179-86.
75. Kakkos SK, Stevens JM, Nicolaides AN, Kyriacou E, Pattichis CS, Geroulakos G, et al. Texture Analysis of Ultrasonic Images of Symptomatic Carotid Plaques can Identify Those Plaques Associated with Ipsilateral Embolic Brain Infarction. Eur J Vasc Endovasc Surg 2007; 33: 422-9.
76. Polak JF, Shemanski L, O'Leary DH, Lefkowitz D, Price TR, Savage PJ, et al. Hypoechoic plaque at US of the carotid artery: An independent risk factor for incident stroke in adults aged 65 years or older. Cardiovascular Health Study. Radiology 1998; 208: 649-54.
77. Liapis CD, Kakisis JD, Kostakis AG. Carotid stenosis: Factors affecting symptomatology. Stroke 2001; 32: 2782-6.
78. Sabetai MM, Coker J, Sheppard M, Nicolaides AN. The association of carotid plaque necrotic core volume and echogenicity with ipsilateral hemispheric symptoms. Circulation 2001; 104(Suppl 2): 671 (abstract).
79. Gronholdt ML, Nordestgaard BG, Bentzon J, Wiebe BM, Zhou J, Falk E, et al. Macrophages are associated with lipid-rich carotid artery plaques, echolucency on B-mode imaging, and elevated plasma lipid levels. J Vasc Surg 2002; 35: 137-45.
80. Gronholdt ML, Nordestgaard BG, Schroeder TV, Vorstrup S, Sillesen H. Ultrasonic echolucent carotid plaques predict future strokes. Circulation 2001; 104: 68-73.
81. Hennerici MG. The unstable plaque. Cerebrovasc Dis 2004; 17(Suppl 3): 17-22.
82. European Carotid Plaque Study Group. Carotid artery plaque composition-relationship to clinical presentation and ultrasound B-mode imaging. Eur J Vasc Endovasc Surg 1995; 10: 23-30.
83. Wilhjelm JE, Gronholdt ML, Wiebe B, Jespersen SK, Hansen LK, Sillesen H. Quantitative analysis of ultrasound B-mode images of carotid atherosclerotic plaque: Correlation with visual classification and histological examination. IEEE Trans Med Imaging 1998; 17: 910-22.
84. Goncalves I, Moses J, Pedro LM, Dias N, Fernandes e Fernandes J, Nilsson J, et al. Echolucency of carotid plaques correlates with plaque cellularity. Eur J Vasc Endovasc Surg 2003; 26: 32-8.
85. Onbas O, Kantarci M, Okur A, Bayraktutan U, Edis A, Ceviz N. Carotid intima-media thickness: Is it correlated with stroke side? Acta Neurol Scand 2005; 111: 169-71.
86. Kalogeropoulos A, Terzis G, Chrysanthopoulou A, Hahalis G, Siablis D, Alexopoulos D. Risk for transient ischemic attacks is mainly determined by intima-media thickness and carotid plaque echogenicity. Atherosclerosis 2006 Jun 12; [Epub ahead of print].
87. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991; 325: 445-53.
88. European Carotid Surgery Trialists Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351: 1379-87.
89. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998; 339: 1415-25.
90. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421-8.
91. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, et al. MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 2004; 363: 1491-502.
92. Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 2006; 114: 1847-54.
93. Liapis CD, Kakisis JD, Dimitroulis DA, Kostakis AG. The impact of the carotid plaque type on restenosis and future cardiovascular events: A 12-year prospective study. Eur J Vasc Endovasc Surg 2002; 24: 239-44.
94. Tegos TJ, Sabetai MM, Nicolaides AN, Robless P, Kalodiki E, Elatrozy TS, et al. Correlates of embolic events detected by means of transcranial Doppler in patients with carotid atheroma. J Vasc Surg 2001; 33: 131-8.
95. Sabetai MM, Tegos TJ, Nicolaides AN, Dhanjil S, Pare GJ, Stevens JM. Reproducibility of computer-quantified carotid plaque echogenicity: Can we overcome the subjectivity? Stroke 2000; 31: 2189-96.
96. Mathiesen EB, Bonaa KH, Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the tromso study. Circulation 2001; 103: 2171-5.
97. O'Leary DH, Polak JF. Intima-media thickness: A tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002; 90(10C): 18L-21L.
98. del Sol AI, Moons KG, Hollander M, Hofman A, Koudstaal PJ, Grobbee DE, et al. Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Stroke 2001; 32: 1532-8
99. McDermott MM, Liu K, Criqui MH, Ruth K, Goff D, Saad MF, et al. Ankle-brachial index and subclinical cardiac and carotid disease: The multi-ethnic study of atherosclerosis. Am J Epidemiol 2005; 162: 33-41.
100. Bocchio M, Scarpelli P, Necozione S, Pelliccione F, Mhialca R, Spartera C, et al. Intima-media thickening of common carotid arteries is a risk factor for severe erectile dysfunction in men with vascular risk factors but no clinical evidence of atherosclerosis. J Urol 2005; 173: 526-9.
101. McNeil AM, Rosamond WD, Girman CJ, Heiss G, Golden SH, Duncan BB, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol 2004; 94: 1249-54.
102. Honda O, Sugiyama S, Kugiyama K, Fukushima H, Nakamura S, Koide S, et al. Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. J Am Coll Cardiol 2004; 43: 1177-84.
103. Kappagoda CT. Counterpoint: Carotid ultrasound-an essential investigation in the prevention of coronary artery disease? Prev Cardiol 2005; 8: 122-4.
104. Liapis CD, Kakisis JD, Dimitroulis DA, Daskalopoulos M, Nikolaou A, Kostakis AG. Carotid ultrasound findings as a predictor of long-term survival after abdominal aortic aneurysm repair: A 14-year prospective study. J Vasc Surg 2003; 38: 1220-5.
105. Kawarada O, Yokoi Y, Morioka N, Nakata S, Higashiue S, Mori T, et al. Carotid stenosis and peripheral artery disease in Japanese patients with coronary artery disease undergoing coronary artery by-pass grafting. Circ J 2003; 67: 1003-6.
106. Rohani M, Jogestrand T, Ekberg M, van der Linden J, Kallner G, Jussila R, et al. Interrelation between the extent of atherosclerosis in the thoracic aorta, carotid intima-media thickness and the extent of coronary artery disease. Atherosclerosis 2005; 179: 311-6.
107. Guo Y, Jiang X, Chen S, Zhang S, Zhao H, Wu Y. Aortic arch and intra-/ extracranial cerebral arterial atherosclerosis in patients suffering acute ischemic strokes. Chin Med J (Engl) 2003; 116: 1840-4.
108. Weinberger J, Papamitsakis N, Newfield A, Godbold J, Goldman M. Plaque morphology correlates with cerebrovascular symptoms in patients with complex aortic arch plaque. Arch Neurol 2000; 57: 81-4.
109. Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, et al. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med 2004; 164: 969-76.
110. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC Study. Kidney Int 2003; 64: 610-5.
111. Gale CR, Ashurst H, Phillips NJ, Moat SJ, Bonham JR, Martyn CN. Renal function, plasma homocysteine and carotid atherosclerosis in elderly people. Atherosclerosis 2001; 154: 141-6.
112. Leskinen Y, Lehtimaki T, Loimaala A, Lautamatti V, Kallio T, Huhtala H, et al. Carotid atherosclerosis in chronic renal failure-the central role of increased plaque burden. Atherosclerosis 2003; 171: 295-302.
113. Higashida RT, Meyers PM, Phatouros CC, Connors JJ 3rd, Barr JD, Sacks D; Technology Assessment Committees of the American Society of Interventional; Therapeutic Neuroradiology and the Society of Interventional Radiology. Reporting standards for carotid artery angioplasty and stent placement. Stroke 2004; 35: E112-34.
114. Mayberg MR, Wilson SE, Yatsu F, Weiss DG, Messina L, Hershey LA, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA 1991; 266: 3289-94.
115. Hobson RW 2nd, Weiss DG, Fields WS, Goldstone J, Moore WS, Towne JB, et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans Affairs Cooperative Study Group. N Engl J Med 1993; 328: 221-7.
116. Findlay JM, Tucker WS, Ferguson GG, Holness RO, Wallace MC, Wong JH. Guidelines for the use of carotid endarterectomy: Current recommendations from the Canadian Neurosurgical Society. CMAJ 1997; 157: 653-9.
117. Chambers BR, You RX, Dorman GA. Carotid endarterectomy for asymptomatic carotid stenosis. Cochrane Database Syst Rev 2000; 2: CD001923.
118. Nicolaides AN, Shiffin EG, Bradbury A, Dhanjil S, Griffin M, Belcaro G, et al. Angiographic and duplex grading of internal carotid stenosis: Can we overcome the confusion? J Endovasc Surg 1996; 3: 158-65.
119. Nicolaides AN. Asymptomatic carotid stenosis and risk of stroke. Identification of a high risk group (ACSRS). Int Angiol 1995; 14: 21-3.
120. CaRESS Steering Committee. Carotid Revascularization Using Endarterectomy or Stenting Systems (CaRESS) phase I clinical trial: 1-year results. J Vasc Surg 2005; 42: 213-9.
121. Boules TN, Proctor MC, Aref A, Upchurch GR Jr, Stanley JC, Henke PK. Carotid endarterectomy remains the standard of care, even in high-risk surgical patients. Ann Surg 2005; 241: 356-63.
122. Biasi GM, Froio A, Diethrich EB, Deleo G, Galimberti S, Mingazzini P, et al. Carotid plaque echolucency increases the risk of stroke in carotid stenting: The Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS) study. Circulation 2004; 110: 756-62.
123. Reiter M, Bucek RA, Effenberger I, Boltuch J, Lang W, Ahmadi R, et al. Plaque echolucency is not associated with the risk of stroke in carotid stenting. Stroke 2006; 37: 2378-80.
124. Rubio F, Martinez-Yelamos S, Cardona P, Krupinski J. Carotid endarterectomy: Is it still a gold standard? Cerebrovasc Dis 2005; 20(Suppl 2): 119-22.
125. O'Rourke F, Dean N, Akhtar N, Shuaib A. Current and future concepts in stroke prevention. CMAJ 2004; 170: 1123-33.
126. Rajamani K, Chaturvedi S. Medical management of carotid artery disease. Semin Neurol 2005; 25: 376-83.
127. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, et al. Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets 2005; 16: 65-71.
128. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
129. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin 2004; 20: 951-4.
130. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34: 1951-6.
131. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005; 11: 4161-75.
132. Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. Int J Clin Pract 2006; 60: 48-56.
133. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004; 55: 589-612.
134. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. Stroke 2004; 35: 2902-9.
135. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
136. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055-60.
137. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110: 3512-7.
138. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
139. Annovazzi A, Bonanno E, Arca M, D'Alessandria C, Marcoccia A, Spagnoli LG, et al. (99m)Tc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging 2006; 33: 117-26.
140. Martin-Ventura JL, Blanco-Colio LM, Gomez-Hernandez A, Munoz-Garcia B, Vega M, Serrano J, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 2005; 36: 1796-800.
141. Durazzo AE, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: A randomized trial. J Vasc Surg 2004; 39: 967-75.
142. Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP. Peripheral arterial disease: A missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 2005; 12: 443-52.
143. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
144. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. CARDS Investigators. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2005; 48: 2482-5.
145. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization. Treatment Investigators. N Engl J Med 1999; 341: 70-6.
146. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233-40.
147. Cashin-Hemphill L, Mack WJ, Pogoda JK Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990; 264: 3013-7.
148. Vigen C, Hodis HN, Selzer RH, Mahrer PR, Mack WJ. Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study). Am J Cardiol 2005; 95: 1277-82.
149. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. REVERSAL Investigators. Effect of intensive compared with
150. Yokoyama H, Kawasaki M, Ito Y, Minatoguchi S, Fujiwara H. Effects of fluvastatin on the carotid arterial media as assessed by integrated backscatter ultrasound compared with pulse-wave velocity. J Am Coll Cardiol 2005; 46: 2031-7.
151. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679-87.
152. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: A randomized controlled clinical trial. Ann Intern Med 1996; 124: 548-56.
153. de Groot E, Jukema JW, van Boven AJ, Reiber JH, Zwinderman AH, Lie KI, et al. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: A report from the Regression Growth Evaluation Statin Study. Am J Cardiol 1995; 76: 40C-6C.
154. Crouse JR 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-11). Am J Cardiol 1995; 75: 455-9.
155. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998; 97: 1784-90.
156. Watanabe K, Sugiyama S, Kugiyama K, Honda O, Fukushima H, Koga H, et al. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 2005; 46: 2022-30.
157. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001; 103: 926-33.
158. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757-67.
159. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: A prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005; 46: 106-12.
160. McGirt MJ, Perler BA, Brooke BS, Woodworth GF, Coon A, Jain S, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 2005; 42: 829-36.
161. Yilmaz A, Lochno M, Traeg F, Cicha I, Reiss C, Stumpf C, et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004; 176: 101-10.
162. Migdalis IN, Gerolimou B, Kozanidou G, Voudouris G, Hatzigakis SM, Petropoulos A. Effect of gemfibrozil on early carotid atherosclerosis in diabetic patients with hyperlipidaemia. Int Angiol 1997; 16: 258-61.
163. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, et al. VA-HIT Study Group. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001; 103: 2828-33.
164. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease
165. LaMuraglia GM, Stoner MC, Brewster DC, Watkins MT, Juhola KL, Kwolek C, et al. Determinants of carotid endarterectomy anatomic durability: effects of serum lipids and lipid-lowering drugs. J Vasc Surg 2005; 41: 762-8.
166. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: A systematic review. Stroke 2003; 34: 2741-8.
167. Amarenco P. Blood pressure and lipid lowering in the prevention of stroke: A note to neurologists. Cerebrovasc Dis 2003; 16(Suppl 3): 33-8.
168. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
169. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-7.
170. McCormack PL, Wagstaff AJ. Lacidipine: A review of its use in the management of hypertension. Drugs 2003; 63: 2327-56.
171. Paliotti R, Ciulla MM, Hennig M, Tang R, Bond MG, Mancia G, et al. Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: An echoreflectivity study. J Hypertens 2005; 23: 1203-9.
172. Zanchetti A, Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 1998; 16: 1667-76.
173. Pontremoli R, Viazzi F, Ravera M, Leoncini G, Berruti V, Bezante GP, et al. Long term effect of nifedipine GITS and lisinopril on subclinical organ damage in patients with essential hypertension. J Nephrol 2001; 14: 19-26.
174. Taddei S, Ghiadoni L, Salvetti A. Current treatment of patients with hypertension: Therapeutic implications of INSIGHT. Drugs 2003; 63: 1435-44.
175. Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949-54.
176. Terpstra WF, May JF, Smit AJ, de Graeff PA, Crijns HJ. Effects of nifedipine on carotid and femoral arterial wall thickness in previously untreated, hypertensive patients. Blood Press Suppl 2003; 1: 22-9.
177. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785-91.
178. Hosomi N, Mizushige K, Ohyama H, Takahashi T, Kitadai M, Hatanaka Y, et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001; 32: 1539-45.
179. Zanchetti A, Crepaldi G, Bon MG, Gallus G, Veglia F, Mancia G, et al. PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: Principal results of PHYLLIS - a randomized double-blind trial. Stroke 2004; 35: 2807-12.
180. Laurent S. Evidence for benefits of perindopril in hypertension and its complications. Am J Hypertens 2005; 18(9 Pt 2): 155S-62S.
181. Uchiyama-Tanaka Y, Mori Y, Kishimoto N, Fukui M, Nose A, Kijima Y, et al. Comparison of the effects of quinapril and losartan on carotid artery intima-media thickness in patients with mild-to-moderate arterial hypertension. Kidney Blood Press Res 2005; 28: 111-6.
182. MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000; 36: 438-43.
183. Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS), Circulation 2001; 103: 1721-6.
184. Wikstrand J, Berglund G, Hedblad B, Hulthe J. Antiatherosclerotic effects of beta-blockers. Am J Cardiol 2003; 91(12A): 25H-9H.
185. Wiklund O, Hulthe J, Wikstrand J, Schmidt C, Olofsson SO, Bondjers G. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: A 3-year randomized study. Stroke 2002; 33: 572-7.
186. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 483S-512S.
187. Antithrombotic Trialists Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002; 324: 71-86.
188. Kodama M, Yamasaki Y, Sakamoto K, Yoshioka R, Matsuhisa M, Kajimoto Y, et al. Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thromb Res 2000; 97: 239-45.
189. Norris JW. Antiplatelet agents in secondary prevention of stroke: A perspective. Stroke 2005; 36: 2034-6.
190. ESPRIT Study Group; Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet 2006; 367: 1665-73.
191. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
192. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HF, Boden WE, et al. CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.
193. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-7.
194. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.
195. Hennerici M, Meairs S. Imaging arterial wall disease. Cerebrovasc Dis 2000; 10(Suppl 5): 9-20.
196. Corot C, Petry KG, Trivedi R, Saleh A, Jonkmanns C, Le Bas JF, et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol 2004; 39: 619-25.
197. Leiner T, Gerretsen S, Botnar R, Lutgens E, Cappendijk V, Kooi E, et al. Magnetic resonance imaging of atherosclerosis. Eur Radiol 2005; 15: 1087-99.
198. Yabushita H, Bouma BE, Houser SL, Aretz HT, Jang IK, Schlendorf KH, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation 2002; 106: 1640-5.
199. van der Meer FJ, Faber DJ, Baraznji Sassoon DM, Aalders MC, Pasterkamp G, van Leeuwen TG. Localized measurement of optical attenuation coefficients of atherosclerotic plaque constituents by quantitative optical coherence tomography. IEEE Trans Med Imaging 2005; 24: 1369-76.
200. Naghavi M, Madjid M, Gul K, Siadaty MS, Litovsky S, Willerson JT, et al. Thermography basket catheter: in vivo measurement of the temperature of atherosclerotic plaques for detection of vulnerable plaques. Catheter Cardiovasc Interv 2003; 59: 52-9.
201. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262-9.
202. Kablak-Ziembicka A, Tracz W, Przewlocki T, Pieniazek P, Sokolowski A, Konieczynska M. Association of increased carotid intima-media thickness with the extent of coronary artery disease. Heart 2004; 90: 1286-90.